NEW YORK (GenomeWeb) — Chiral Technologies said today that it has acquired next-generation sequencing and synthetic biology products provider Arbor Biosciences.
Arbor's portfolio includes custom DNA microarrays and oligonucleotide libraries, as well as its myBaits line of targeted sequencing panels. The company also offers a cell-free protein expression kit and custom, error-free DNA templates for the transcription of guide RNAs for CRISPR research.
According to Chiral, Arbor will continue to operate at its current location in Ann Arbor, Michigan and will retain its entire team. It will operate as a wholly owned subsidiary of Japan's Daicel, Chiral's parent firm. Additional terms of the acquisition were not disclosed.
"As we diversify our product portfolio to serve the needs of biopharma, Arbor Biosciences delivers the molecular biology foundation to fuel that growth," Chiral President Joseph Barendt said in a statement.
West Chester, Pennsylvania-based Chiral also acquired DNA purification firm Diffinity Genomics in 2015.